Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 1, 2009, Pages 63-68

  Carey, John C ^a,b,c   Martinez, Lynn ^b   Balken, Elizabeth ^b   Leen Mitchell, Marsha ^b   Robertson, Julia ^b   Utah, ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UTAH DEPARTMENT OF HEALTH   (United States)

^c NONE   (United States)

Author keywords

Antley Bixler syndrome; Cutis laxa; Fluconazole; Microtia; Mycophenolate mofetil; Penicillamine; Teratogenicity

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE; TACROLIMUS; TERATOGENIC AGENT; ANTIFUNGAL AGENT; ANTIRHEUMATIC AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ANOPHTHALMIA; ANTLEY BIXLER SYNDROME; ARTHROGRYPOSIS; BONE BOWING; CARDIOVASCULAR MALFORMATION; CLEFT LIP PALATE; CLEFT PALATE; CLINICAL FEATURE; COLOBOMA; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; CUTIS LAXA; DRUG EXPOSURE; DRUG MEGADOSE; EAR MALFORMATION; EMBRYOPATHY; HUMAN; HUMERAL RADIAL SYNOSTOSIS; HYDROPS; JOINT CONTRACTURE; MICROPHTHALMIA; MICROTIA; NONHUMAN; ORBIT HYPOPLASIA; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKELETON MALFORMATION; TECHNIQUE; TERATOGENICITY; TRACHEOESOPHAGEAL FISTULA; CASE REPORT; CONGENITAL DISORDER; CONGENITAL MALFORMATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; FETUS; NEWBORN; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANTIFUNGAL AGENTS; ANTIRHEUMATIC AGENTS; CONGENITAL ABNORMALITIES; EVIDENCE-BASED MEDICINE; FEMALE; FETUS; FLUCONAZOLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MYCOPHENOLIC ACID; PENICILLAMINE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; TERATOGENS;

EID: 59849102866     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20533     Document Type: Review

References (35)

1. Adachi I, Tachibana K, Asakura Y, et al. 2004. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene in two patients with Antley-Bixler syndrome. Amer J Med Genet Part A 128A:333-339.
2. Aleck KA, Bartley DL. 1997. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Amer J Med Genet 72:253-256.
3. Brent RL. 1986. Evaluating the alleged teratogenicity of environmental agents. Clin Perinatol 13:609-613.
4. Brent RL. 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litogen. Repod Toxicol 9:337-349.
5. Brent RL. 1993. Congenital malformation case reports: the editor and reviewer's dilemma. Amer J Med Genet 47:872-874.
6. Brent RL. 2004. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 113:957-968.
7. Briggs GG, Freeman RK, and Yaffe SJ. 2005. Drugs in pregnancy and lactation. 7th ed. Philadelphia: Lippincott Williams and Wilkins.
8. Byers PH, Siegel RC, Holbrook KA, et al. 1980. X-Linked cutis laxa: defective collagen crosslink formation due to decreased lysyl oxidase activity. New Eng J Med 303:61-65.
9. Carey JC. 2002. Editor's note. Am J Med Genet 111:54.
10. Carey JC. 2008. "Where observation is concerned, chance favors only the prepared mind". Obestet Gynecol 111:479-480.
11. El Sebaaly Z, Charpentier B, Snanoudjr. 2007. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22:2722-2732.
12. Fluck CE, Tajima T, Pandley AV, et al. 2004. Mutant P459 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36:228-230.
13. Holmes LB. 1999. Commentary: pediatric research. 45:286-287.
14. Jackson PY, Pakette L, Ramanthan R, et al. 2008. Mycophenolate mofetil as a teratogen. J Investig Med 56:196A.
15. Jorde L, Carey JC, Bamshad M, White R. 2003. Medical genetics. Mosby/Elsevier Science. St. Louis, p. 319.
16. Kelley RI, Kratz LE, Glaser RL, et al. 2002. Abnormal sterometabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 110:95-102.
17. Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Eng J Med 313:837-41.
18. Le Ray C, Coulomb A, Elefant E et al. 2004. Myocophenalate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103:1099-1094.
19. Lopez-Rangel E, Van Allen MI. 2005. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 73:919-923.
20. Mark-Savage P, Keen CL, Hurloy LS. 1983. Reduction by copper supplementation of teratogenic effects of D-ponicillamine. J Nutr 113:501-510.
21. Martínez-Frías ML, Bermejo E, Rodriquez-Pinilla E, Frias JL. 2004. Risk for congenital anomalies associated with different sporadic and daily doses of alcohol consumption during pregnancy: a case-control study. Birth Defects Res A Clin Mol Teratol 70:194-200.
22. Mastroiacova P, Mazzone T, Botto LD, et al. 1996. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 175:1645-1650.
23. Miller RW. 2004. How environmental hazards in childhood have been discovered: carcinogens, teratogens, neurotoxins, and others. Pediatrics 113:945-950.
24. Perez-Aytes A, Ledo A, Boso V, et al. 2008. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 146A:1-7.
25. Pinter R, Hogge WA, McPherson E. 2004. Infant with severe penicillamine embryopathy born to a mother with Wilson disease. Am J Med Genet A 128A:294-298.
26. Plotkin SA. 2006. History of rubella and rubella vaccination leading to elimination. Clin Infect Dis 43:S164-S168.
27. Rasmussen SA, Hayes EB, Jamieson DJ, et al. 2007. Emerging infections in pregnancy assessing the impact on the embryo or fetus. Am J Med Genet A 143A:2896-2903.
28. Schoner K, Steinhard J, Figiel J, et al. 2008. Severe facial clefts and acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol 111:483-486.
29. Shepard TH. 1994. Proof of human teratogenicity. Teratology 50:97-98.
30. Shepard TH. 1991. Editorial reply to "Comments on Moebius syndrome: animal model-human correlations and evidence for a brainstem vascular etiology: case observation versus epidemiology studies". Teratology 43:559-560.
31. Sifontis NM, Coscia LA, Constaninescu S et al. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702.
32. Sorensen HT, Nielsen GL, Olesen C, et al. 1999. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 48:234-238.
33. Tiboni GM, Iammarrone E, Giampietro F et al. 1999. Teratologic interaction between bis-triazole antifungal fluconazole and the anticonvulsant phenytoin. Teratology 59:81-87.
34. Tjeertes IF, Bastiaans DE, van Ganzewinkel CJ, et al. 2007. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil. J Perinatol 27:62-64.
35. Velino VM, Zellers N. 2008. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol 17:77-78.